Clinical trials: Germ Cell Tumour
Metastatic Melanoma
Taxoprexin® Treatment for Advanced Eye Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00244816
- Testing
- Taxoprexin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- American Regent, Inc.
Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma…
- Trial name
- CENTRIC (NCT00689221)
- Testing
- Cilengitide, Temozolomide, Radiotherapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 545 people
- Sponsor
- EMD Serono
Melanoma
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma.
- Trial name
- NCT00324155
- Testing
- Ipilimumab, Dacarbazine
- Where
- 127 sites in United States, Argentina and 23 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Melanoma
Trial of pIL-12 Electroporation Malignant Melanoma
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene…
- Trial name
- IL-12MEL (NCT01502293)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoSec Medical Incorporated
Recurrent Glioblastoma
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
- Trial name
- NCT05191784
- Testing
- GX-I7, Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Genexine, Inc.
Malignant Melanoma, Skin
Intratumoral Administration of L19IL2/L19TNF
This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a.
- Trial name
- NCT02076633
- Testing
- L19IL2+L19TNF
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Philogen S.p.A.
Glioblastoma
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
- Trial name
- NCT00171938
- Testing
- imatinib mesylate
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Novartis
Recurrent or Progressive Malignant Glioma
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma.
- Trial name
- NCT00539344
- Testing
- ANG1005
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Angiochem Inc
Merkel Cell Carcinoma
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
- Trial name
- NCT04874831
- Testing
- domatinostat in combination with avelumab
- Sponsor
- 4SC AG
Melanoma
A Study of GC101 TIL in Advanced Melanoma
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
- Trial name
- MIZAR-003 (NCT06703398)
- Testing
- GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Unresectable Melanoma, Metastatic Melanoma
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or…
- Trial name
- CheckMate 069 (NCT01927419)
- Testing
- Nivolumab, Ipilimumab
- Where
- 21 sites in United States, France
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
Non-interventional (observational) cohort prospective real life study with primary and secondary data collection from patients on adjuvant treatment with dabrafenib + trametinib in patients with completely resected high-risk…
- Trial name
- LEAD Melanoma (NCT04961619)
- Testing
- dabrafenib, trametinib
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Astrocytoma
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
The objective of this study is to investigate tolerability, safety, pharmacokinetics (PK) and efficacy of oral OKN-007 in participants with recurrent high-grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- NCT03649464
- Testing
- OKN-007
- Sponsor
- Oblato, Inc.
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor, Recurrent Glioma
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options.
- Trial name
- NCT04089449
- Testing
- PRT811
- Where
- 11 sites in United States
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Malignant Melanoma, Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body.
- Conditions
- Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
- Trial name
- NCT06799533
- Testing
- PF-08046031
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.